WHC is still in active development. Read this to understand our approach.
depiction of RDOIQAHITMMDAJ-UHFFFAOYSA-N.svg
isomerdesign

Loperamide

Check on isomerdesign

pubchem

Loperamide

Check on pubchem

drugmap

Loperamide

Check on drugmap

wiki

Loperamide

Check on wiki

Data

InChI: InChI=1S/C29H33ClN2O2/c1-31(2)27(33)29(24-9-5-3-6-10-24,25-11-7-4-8-12-25)19-22-32-20-17-28(34,18-21-32)23-13-15-26(30)16-14-23/h3-16,34H,17-22H2,1-2H3

Synonyms: DB00836,LOPERAMIDE [MI],BRD-K61250553-001-02-9,Loperamidum [INN-Latin],CBiol_001796,BDBM50017698,EINECS 258-416-5,Lopac0_000708,Prestwick3_000144,KBio2_005237,NCGC00015608-02,NCGC00015608-06,Loperamida [INN-Spanish],FT-0657293,NCGC00015608-05,BRD-K61250553-003-16-5,Loperamide [INN:BAN],Maalox Anti-Diarrheal,Ioperamide,DSSTox_GSID_45165, Kaopectate II, Loperacap, R-18553,Imodium, Dimor (TN),PMS-Loperamide,Bio2_000581,Lopac-L-4762,SPBio_001816,NCGC00015608-08, Maalox Anti-Diarrheal,Tox21_110180_1,Diamide (TN),EC 258-416-5,Nu-Loperamide,Loperacap, Loperamidum,4-(4-Chlorophenyl)-N,N-dimethyl-.alpha.,.alpha.-diphenyl-4-hydroxy-1-piperidinebutanamide,KBio2_003422,Tox21_110180,GTPL7215,NCGC00015608-04,Spectrum3_001015, Pepto Diarrhea Control,2-methoxyethyl1-methylethyl2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate,Spectrum4_001143,BSPBio_000248,CHEMBL841,Tocris-0840,Loperamide,NCGC00024818-04,AB00053697-13, Diamide (TN),NCGC00016828-01,Kaopectate II,LOPERAMIDE OXIDE MONOHYDRATE IMPURITY A [EP IMPURITY],ZINC537928,Fortasec,DivK1c_000215, Apo-Loperamide,1-Piperidinebutanamide, 4-(4-chlorophenyl)-4-hydroxy-N,N-dimethyl-.alpha.,.alpha.-diphenyl-,UNII-6X9OC3H4II,BPBio1_000274, Rho-Loperamide,SPBio_002187,Bio1_000082,NCGC00015608-07,LOPERAMIDE [WHO-DD], Lopex (TN),Prestwick1_000144,NCGC00015608-01,4-[4-(4-Chloro-phenyl)-4-hydroxy-piperidin-1-yl]-N,N-dimethyl-2,2-diphenyl-butyramide(loperamide),L000709, Diarr-Eze,SCHEMBL28530,NCGC00015608-24,BSPBio_001381,1-Piperidinebutanamide, 4-(4-chlorophenyl)-4-hydroxy-N,N-dimethyl-alpha,alpha-diphenyl-,NCGC00015608-11,5-21-02-00379 (Beilstein Handbook Reference),4-(p-Chlorophenyl)-4-hydroxy-N,N-dimethyl-.alpha.,.alpha.-diphenyl-1-piperidinebutyramide,4-[4-(4-Chloro-phenyl)-4-hydroxy-piperidin-1-yl]-N,N-dimethyl-2,2-diphenyl-butyramide,NCGC00024818-03,DSSTox_CID_25165,AB00053697,KBio3_000201,EN300-708764,Q423751,NCGC00024818-02,SBI-0050686.P003,Oprea1_109220,IDI1_033851,AB00053697-12,DTXSID6045165,KBio2_005990, Loperamida,LOPERAMIDE [JAN],LOPERAMIDE [VANDF],C07080,cid_71420,KBioSS_000854,Loperamida,NINDS_000215,4-[4-(4-chlorophenyl)-4-hydroxypiperidin-1-yl]-N,N-dimethyl-2,2-diphenylbutanamide,LOPERAMIDE [INN],AKOS000573892,Imodium A-D,DSSTox_RID_80715,Spectrum2_001738, Pepto (TN),AB00053697_14,Apo-Loperamide,AB00053697_15,NCGC00015608-09,CAS-53179-11-6,NCGC00015608-15,BRN 1558273,NCGC00024818-01,LoperamideHCl,6X9OC3H4II,179L116,STK042086,KBio3_000202,HMS1989F03,4-(4-Chlorophenyl)-N,N-dimethyl-alpha,alpha-diphenyl-4-hydroxy-1-piperidinebutanamide,Bio1_001060, Loperamide (INN),HMS1791F03, Imodium (TN), Loperamide Monohydrochloride,CHEBI:6532,D08144,KBio2_000101,Loperamidum,Prestwick0_000144,4-(4-(4-chlorophenyl)-4-hydroxypiperidin-1-yl)-N,N-dimethyl-2,2-diphenylbutanamide,loperamide,4-[4-(4-Chlorophenyl)-4-hydroxy-1-piperidyl]-N,N-dimethyl-2,2-diphenyl-butanamide,Bio1_000571,HMS2089C13,NCGC00024818-05,Immodium, Loperamida [INN-Spanish],Spectrum_000374, Imodium A-D Caplets,KBio3_001989,CAS-34552-83-5,HSDB 8344,Spectrum5_001374,BRD-K61250553-003-05-8,Loperamide (INN), Loperamidum [INN-Latin],BSPBio_002769,53179-11-6,CCG-204793,KBio1_000215,IDI1_000215,4-[4-(4-Chlorophenyl)-4-hydroxy-1-piperidinyl]-N,N-dimethyl-2,2-diphenylbutanamide #,Imodium A-D Caplets,A829430,NCGC00015608-03, PMS-Loperamide,Prestwick2_000144,KBioSS_000101, Loperamide [INN:BAN],SDCCGSBI-0050686.P004,KBioGR_000101,Bio2_000101,KBio2_000854,KBioGR_001685, Nu-Loperamide,KBio2_002669,Rho-Loperamide

Estimated data

Solubility: -4.761 (log(S) in mol/L prediction using SolTranNet)

Blood Brain Barrier Permeability: Yes (prediction using frontiersin.org)

Addictivity Prediction: 52.3% (prediction based on www.mdpi.com)

Similarities

The following is a set of comparisons to understand the properties of this compound. This is still higly experimental and is still under active development. Please refer to our series of blog posts to fully understand our approach and its limitations. This information is for informational purposes only and should not be construed as medical advice.